Drug
Danvatirsen clinical trials
Also written AZD9150 and ISIS 481464.
- studies test it
- 12
- open now
- 1
- in phase 3
- 0
- first study started
- 2012
Keep track of what changes. Save the danvatirsen studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 2 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 8
- Phase 2
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 3
AstraZeneca (5) · M.D. Anderson Cancer Center (1) · Acerta Pharma BV (1) · MedImmune LLC (1) · Ionis Pharmaceuticals, Inc. (1) · Montefiore Medical Center (1) · Flamingo Therapeutics NV (1) · National Cancer Institute (NCI) (1)
Often tested with
Tested in the same studies.
Durvalumab (5) · Olaparib (2) · Vistusertib (2) · Ceralasertib (2) · AZD4547 (1) · Adavosertib (1) · AZD 6244 (1) · Oleclumab (1)
Studies
Open first, then newest update. How each study uses danvatirsen is read from its arms, and is right about nine times in ten.
Testing it · 12
- Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AMLRecruitingPhase 1Montefiore Medical CenterNCT05986240Written as Danvatirsen
- Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder CancerActive, not recruitingPhase 1AstraZenecaNCT02546661Written as AZD9150
- Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & NeckCompletedPhase 1/2AstraZenecaNCT02499328Written as AZD9150
- Activity and Safety of Danvatirsen and Pembrolizumab in HNSCCTerminatedPhase 2Flamingo Therapeutics NVNCT05814666Written as Danvatirsen
- Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing TherapyActive, not recruitingPhase 2AstraZenecaNCT03334617Written as Danvatirsen
- Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal CancerActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT02983578Written as Danvatirsen
- Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)CompletedPhase 1Acerta Pharma BVNCT03527147Written as AZD9150
- Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid MalignanciesCompletedPhase 1AstraZenecaNCT03394144Written as AZD9150, Durvalumab
- MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)CompletedPhase 1MedImmune LLCNCT02549651Written as AZD9150
- Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced CancersCompletedPhase 1/2Ionis Pharmaceuticals, Inc.NCT01563302Written as IONIS-STAT3Rx
- AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant AscitesTerminatedPhase 2National Cancer Institute (NCI)NCT02417753Written as AZD9150
- A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular CarcinomaCompletedPhase 1AstraZenecaNCT01839604Written as AZD9150
Given in every arm · 3 — danvatirsen is usual care beside what is tested
- A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLCActive, not recruitingPhase 1AstraZenecaNCT03819465Written as Danvatirsen
- AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung CancerCompletedPhase 1AstraZenecaNCT03421353Written as AZD9150
- Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung CancerCompletedPhase 2MedImmune LLCNCT03794544Written as Danvatirsen
Codes
What other systems call danvatirsen · ClinicalTrials.gg INT000529
- MeSH (NLM) C000610954danvatirsenConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 31N550RD05DANVATIRSENConfirmed FDA, NLM
- NCI Thesaurus C101368DanvatirsenOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000610954 | danvatirsen | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 31N550RD05 | DANVATIRSEN | Confirmed FDA, NLM |
| NCI Thesaurus | C101368 | Danvatirsen | One source FDA |
Also registered as danvatirsen sodium (UNII S6A2UYH57V).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.